medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-24-31-37medalphabet-2833Research ArticleСтатьиРастительные средства как способ лечения доброкачественной патологии и профилактики злокачественных новообразований молочной железыHerbal remedies as a way to treat benign pathology of the mammary glandhttps://orcid.org/0000-0001-5541-3767КузнецоваИ. В.KuznetsovaI. V.

Кузнецова Ирина Всеволодовна, д. м. н., профессор

Москва

Kuznetsova Irina V., DM Sci (habil.), professor

Moscow

ms.smith.ivk@gmail.comМедицинская корпорация «РАНА»РоссияMedical Corporation ‘RHANA’Russian Federation202220112022024Современная гинекология (2)3137Copyright © Кузнецова И.В., 20222022Кузнецова И.В.Kuznetsova I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2833

Нарушения нейроэндокринного гомеостаза в стрессовых условиях на фоне повышенного эстрогенного присутствия в тканях могут стать стимулом к развитию доброкачественной патологии молочной железы масталгии, так и в виде доброкачественной дисплазии молочной железы (ДДМЖ), одним из симптомов которых также может стать масталгия. С 2009 г. диагностика и лечение доброкачественной патологии молочной железы находится в ведении гинеколога, и это правильно, поскольку патогенетическая общность болевых синдромов и заболеваний, связанных с аномальной пролиферацией, очевидна в гинекологической практике.

Целью лечения масталгии является улучшение качества жизни пациентки, но если масталгия имеет под собой морфологический субстрат в виде ДДМЖ, то помимо обезболивания необходимо предусмотреть сдерживание прогрессии заболевания для снижения риска развития рака молочной железы. Гормональное лечение здесь имеет ограниченные возможности, и поиски терапевтических концепций обычно ведутся в направлении терапии молекулами растительного происхождения, способными оказывать влияние на метаболизм эстрогенов в тканях. Кроме этого рычага воздействия на процессы аномальной пролиферации в молочной железе, существуют иные мишени, вовлеченные в патофизиологию аномальной пролиферации и боли в молочной железе, в частности, окислительный стресс, иммунная система и др. В этой связи представляют интерес молекулы с плейотропным биологическим действием, такие как ресвератрол, одновременно проявляющие свойства фитоэстрогена, антиоксиданта, инсулиносенситайзера и т. д. Комбинация ресвератрола и индол-3-карбинола для терапии циклической масталгии и ДДМЖ представляется привлекательным вариантом улучшения качества жизни и профилактики злокачественных новообразований.

Violations of neuroendocrine homeostasis under stressful conditions against the background of increased estrogen presence in tissues can become a stimulus for the development of benign breast pathology, both in the form of pain syndrome – cyclic mastalgia, less often non-cyclic mastalgia, and in the form of benign breast dysplasia (DMDM), one of symptoms of which can also be mastalgia. The diagnosis and treatment of benign breast pathology has been the responsibility of a gynecologist since 2009. This is correct, the pathogenetic commonality of pain syndromes and diseases associated with abnormal proliferation is obvious in gynecological practice. The goal of treating mastalgia is to improve the quality of life of the patient, but if mastalgia has a morphological substrate in the form of DMDM, then in addition to pain relief. It is necessary to provide for curbing the progression of the disease to reduce the risk of developing breast cancer. Hormonal treatment has limited possibilities here and the search for therapeutic concepts is usually carried out in the direction of therapy with plant-derived molecules that can influence the metabolism of estrogens in tissues. In addition to this lever of influence on the abnormal proliferation processes abnormal proliferation in the mammary gland, there are other targets involved in the pathophysiology of abnormal proliferation and pain in the mammary gland, in particular, oxidative stress, the immune system, etc. In this regard, molecules with pleiotropic biological effects are of interest, such as resveratrol, simultaneously exhibiting the properties of phytoestrogen, antioxidant, insulin sensitizer, etc. The combination of resveratrol and indole-3-carbinol for the treatment of cyclic mastalgia and DMDM seems to be an attractive option for improving the quality of life and preventing malignant neoplasms.

масталгиядоброкачественная дисплазия молочной железыриск рака молочной железыонкопрофилактикаантиоксидантыметаболизм эстрогеновиндол‑3-карбинолресвератролтранс-ресвератролmastalgiabenign breast dysplasiabreast cancer riskcancer preventionantioxidantsestrogen metabolismindole‑3-carbinolresveratroltrans-resveratrolReferencesКаприн А. Д., Рожкова Н. И. Маммология: национальное руководство. М.: ГЭОТАР-Медиа, 2016; 311 с.Kaprin A. D., Rozhkova N. I. Mammology: a national guide. M.: GEOTAR-Media, 2016; 311 p.Керчелаева С. Б., Сметник А. А., Беспалов В. Г. Мастопатия и профилактика рака молочной железы как междисциплинарная проблема. РМЖ. Мать и дитя. 2016;(15):1018–1025.Kerchelaeva S. B., Smetnik A. A., Bespalov V. G. Mastopathy and prevention of breast cancer as an interdisciplinary problem. BC. Mother and child. 2016;(15):1018–1025.Weaver M., Stuckey A. Benign Breast Disorders. Obstet. Gynecol. Clin. North. Am. 2022; 49(1): 57–72. doi: 10.1016/j.ogc.2021.11.003Weaver M., Stuckey A. Benign Breast Disorders. Obstet. Gynecol. Clin. North. Am. 2022; 49(1): 57–72. doi: 10.1016/j.ogc.2021.11.003Kataria K., Dhar A., Srivastava A., Kumar S., Goyal A. A systematic review of current understanding and management of mastalgia. Indian. J. Surg. 2014;76(3):217–222. doi: 10.1007/s12262–013–0813–8Kataria K., Dhar A., Srivastava A., Kumar S., Goyal A. A systematic review of current understanding and management of mastalgia. Indian. J. Surg. 2014;76(3):217–222. doi: 10.1007/s12262–013–0813–8Рожкова Н. И., Зикиряходжаев А. Д., Бурдина И. И., Ермощенкова М. В., Запирова С. П., Мазо М. Л. и др. Доброкачественные заболевания молочной железы. М.: ГЭОТАР-Медиа. 2018; 272.Rozhkova N. I., Zikiryakhodzhaev A. D., Burdina I. I., Ermoshchenkova M. V., Zapirova S. P., Mazo M. L. et al. Benign diseases of the mammary gland. Moscow: GEOTAR-Media. 2018; 272.Dyrstad S. W., Yan Y., Fowler A. M., Colditz G. A. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast. Cancer. Res. Treat. 2015;149(3):569–575. doi: 10.1007/s10549–014–3254–6Dyrstad S. W., Yan Y., Fowler A. M., Colditz G. A. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast. Cancer. Res. Treat. 2015;149(3):569–575. doi: 10.1007/s10549–014–3254–6Houghton S. C., Hankinson S. E. Cancer Progress and Priorities: Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(5):822–844. doi: 10.1158/1055–9965.EPI-20–1193Houghton S. C., Hankinson S. E. Cancer Progress and Priorities: Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(5):822–844. doi: 10.1158/1055–9965.EPI-20–1193Щепотин И. Б., Зотов А. С., Любота Р. В., Аникусько Н. Ф., Любота И. И. Основные механизмы влияния метаболического синдрома на риск возникновения и прогноз течения рака молочной железы (обзор литературы). Опухоли женской репродуктивной системы. 2013;1–2:45–51.Schepotin I. B., Zotov A. S., Lyubota R. V., Anikusko N. F., Lyubota I. I. The main mechanisms of the influence of the metabolic syndrome on the risk of occurrence and prognosis of the course of breast cancer (literature review). Tumors of the female reproductive system. 2013;1–2:45–51Liu H., Shi S., Gao J., Guo J., Li M., Wang L. Analysis of risk factors associated with breast cancer in women: a systematic review and meta-analysis. Transl. Cancer. Res. 2022;11(5):1344–1353. doi: 10.21037/tcr-22–193Liu H., Shi S., Gao J., Guo J., Li M., Wang L. Analysis of risk factors associated with breast cancer in women: a systematic review and meta-analysis. Transl. Cancer. Res. 2022;11(5):1344–1353. doi: 10.21037/tcr-22–193Toktaş O., Elasan S., İliklerden Ü. H., Erten R., Karayil A. R., Özdemir A. et al. Relationship Between Proliferative Breast Lesions and Breast Cancer Risk Factors. Eur. J. Breast. Health. 2020;17(1):15–20. doi: 10.4274/ejbh.2020.5713Toktaş O., Elasan S., İliklerden Ü. H., Erten R., Karayil A. R., Özdemir A. et al. Relationship Between Proliferative Breast Lesions and Breast Cancer Risk Factors. Eur. J. Breast. Health. 2020;17(1):15–20. doi: 10.4274/ejbh.2020.5713Salamat F., Niakan B., Keshtkar A., Rafiei E., Zendehdel M. Subtypes of Benign Breast Disease as a Risk Factor of Breast Cancer: A Systematic Review and Meta Analyses. Iran. J. Med. Sci. 2018;43(4):355–364.Salamat F., Niakan B., Keshtkar A., Rafiei E., Zendehdel M. Subtypes of Benign Breast Disease as a Risk Factor of Breast Cancer: A Systematic Review and Meta Analyses. Iran. J. Med. Sci. 2018;43(4):355–364.Лабазанова П. Г., Буданова М. В., Бурдина И. И., Запирова С. Б., Мазо М. Л., Микушин С. Ю. и др. Маммографическая плотность – маркер повышенного риска развития рака молочной железы. Медицинский алфавит. 2021;19:41–48.Labazanova P. G., Budanova M. V., Burdina I. I., Zapirova S. B., Mazo M. L., Mikushin S. Yu. et al. Mammographic density is a marker of an increased risk of developing breast cancer. Medical Alphabet. 2021;19:41–48.Kontos D., Winham S. J., Oustimov A., Pantalone L., Hsieh M. K., Gastounioti A. et al. Radiomic Phenotypes of Mammographic Parenchymal Complexity: Toward Augmenting Breast Density in Breast Cancer Risk Assessment. Radiology. 2019;290(1):41–49. doi: 10.1148/radiol.2018180179Kontos D., Winham S. J., Oustimov A., Pantalone L., Hsieh M. K., Gastounioti A. et al. Radiomic Phenotypes of Mammographic Parenchymal Complexity: Toward Augmenting Breast Density in Breast Cancer Risk Assessment. Radiology. 2019;290(1):41–49. doi: 10.1148/radiol.2018180179Lisanti M. P., Tsirigos A., Pavlides S., Reeves K. J., Peiris-Pagès M., Chadwick A. L. et al. JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: connecting fibrosis, inflammation, and stemness for cancer prevention. Cell. Cycle. 2014;13(4):580–599. doi: 10.4161/cc.27379Lisanti M. P., Tsirigos A., Pavlides S., Reeves K. J., Peiris-Pagès M., Chadwick A. L. et al. JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: connecting fibrosis, inflammation, and stemness for cancer prevention. Cell. Cycle. 2014;13(4):580–599. doi: 10.4161/cc.27379Ziegler R. G. Epidemiologic studies of estrogen metabolism and breast cancer. Steroids. 2015;99(PtA):67–75. doi: 10.1016/j.steroids.2015.02.015Ziegler R. G. Epidemiologic studies of estrogen metabolism and breast cancer. Steroids. 2015;99(PtA):67–75. doi: 10.1016/j.steroids.2015.02.015Katz V. L., Dotters D. Breast Diseases: Diagnosis and Treatment of Benign and Malignant Disease. In: Katz VL, Lentz GM, Lobo RA, Gershenson DM, Eds., Comprehensive Gynecology, 6th Edition, Elsevier Mosby, Philadelphia: 2012Katz V. L., Dotters D. Breast Diseases: Diagnosis and Treatment of Benign and Malignant Disease. In: Katz VL, Lentz GM, Lobo RA, Gershenson DM, Eds., Comprehensive Gynecology, 6th Edition, Elsevier Mosby, Philadelphia: 2012Ашрафян Л. А., Бабаева Н. А., Антонова И. Б., Алешикова О. И., Герфанова Е. В. Значение эстрогенных метаболитов в канцерогенезе опухолей женской репродуктивной системы // Медицинский оппонент. 2019;3(7): 34–39.Ashrafyan L. A., Babaeva N. A., Antonova I. B., Alyoshikova O. I., and Gerfanova E. V., Russ. The value of estrogen metabolites in the carcinogenesis of tumors of the female reproductive system. Medical opponent. 2019;3(7): 34–39.Zheng R., Wang J., Wu Q., Wang Z., Ou Y., Ma L. et al. Expression of ALDH1 and TGFβ2 in benign and malignant breast tumors and their prognostic implications. Int. J. Clin. Exp. Pathol. 2014;7(7):4173–4183.Zheng R., Wang J., Wu Q., Wang Z., Ou Y., Ma L. et al. Expression of ALDH1 and TGFβ2 in benign and malignant breast tumors and their prognostic implications. Int. J. Clin. Exp. Pathol. 2014;7(7):4173–4183.Ilango S., Paital B., Jayachandran P., Padma P. R., Nirmaladevi R. Epigenetic alterations in cancer. Front. Biosci. (Landmark Ed). 2020;25(6):1058–1109. doi: 10.2741/4847Ilango S., Paital B., Jayachandran P., Padma P. R., Nirmaladevi R. Epigenetic alterations in cancer. Front. Biosci. (Landmark Ed). 2020;25(6):1058–1109. doi: 10.2741/4847Spitzwieser M., Holzweber E., Pfeiler G., Hacker S., Cichna-Markl M. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer. Breast. Cancer. Res. 2015;17(1):125. doi: 10.1186/s13058–015–0637–5Spitzwieser M., Holzweber E., Pfeiler G., Hacker S., Cichna-Markl M. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer. Breast. Cancer. Res. 2015;17(1):125. doi: 10.1186/s13058–015–0637–5Jin W., Li Q. Z., Liu Y., Zuo Y. C. Effect of the key histone modifications on the expression of genes related to breast cancer. Genomics. 2020;112(1):853–858. doi: 10.1016/j.ygeno.2019.05.026Jin W., Li Q. Z., Liu Y., Zuo Y. C. Effect of the key histone modifications on the expression of genes related to breast cancer. Genomics. 2020;112(1):853–858. doi: 10.1016/j.ygeno.2019.05.026Pandima Devi K., Rajavel T., Daglia M., Nabavi S. F., Bishayee A., Nabavi S. M. Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer. Semin. Cancer. Biol. 2017;46:146–157. doi: 10.1016/j.semcancer.2017.02.001Pandima Devi K., Rajavel T., Daglia M., Nabavi S. F., Bishayee A., Nabavi S. M. Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer. Semin. Cancer. Biol. 2017;46:146–157. doi: 10.1016/j.semcancer.2017.02.001Minning C., Mokhtar N. M., Abdullah N., Muhammad R., Emran N. A., Ali S. A. et al. Exploring breast carcinogenesis through integrative genomics and epigenomics analyses. Int. J. Oncol. 2014;45(5):1959–1968. doi: 10.3892/ijo.2014.2625Minning C., Mokhtar N. M., Abdullah N., Muhammad R., Emran N. A., Ali S. A. et al. Exploring breast carcinogenesis through integrative genomics and epigenomics analyses. Int. J. Oncol. 2014;45(5):1959–1968. doi: 10.3892/ijo.2014.2625Kleffel S., Schatton T. Tumor dormancy and cancer stem cells: two sides of the same coin? Adv. Exp. Med. Biol. 2013;734:145–179. doi: 10.1007/978–1–4614–1445–2_8Kleffel S., Schatton T. Tumor dormancy and cancer stem cells: two sides of the same coin? Adv. Exp. Med. Biol. 2013;734:145–179. doi: 10.1007/978–1–4614–1445–2_8Recasens A., Munoz L. Targeting Cancer Cell Dormancy. Trends. Pharmacol. Sci. 2019;40(2):128–141. doi: 10.1016/j.tips.2018.12.004Recasens A., Munoz L. Targeting Cancer Cell Dormancy. Trends. Pharmacol. Sci. 2019;40(2):128–141. doi: 10.1016/j.tips.2018.12.004Wong C. P., Hsu A., Buchanan A., Palomera-Sanchez Z., Beaver L. M., Houseman E. A. et al. Effects of sulforaphane and 3,3’-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One. 2014;9(1): e86787. doi: 10.1371/journal.pone.0086787Wong C. P., Hsu A., Buchanan A., Palomera-Sanchez Z., Beaver L. M., Houseman E. A. et al. Effects of sulforaphane and 3,3’-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One. 2014;9(1): e86787. doi: 10.1371/journal.pone.0086787Tijhuis A. E., Johnson S. C., McClelland S. E. The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity. Mol. Cytogenet. 2019;12:17. doi: 10.1186/s13039–019–0429–1Tijhuis A. E., Johnson S. C., McClelland S. E. The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity. Mol. Cytogenet. 2019;12:17. doi: 10.1186/s13039–019–0429–1Сотникова Л. С., Голубятникова Е. В. К вопросу эффективности терапии доброкачественной патологии молочных желез. Эффективная фармакотерапия. 2016; 4(31)12–21.Sotnikova L. S., Golubyatnikova E. V. To the question of the effectiveness of therapy for benign pathology of the mammary glands. effective pharmacotherapy. 2016; 4(31)12–21.Thompson P. A., Khatami M., Baglole C. J., Sun J., Harris S. A., Moon E. Y. et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis. 2015;36(Suppl 1): S 232–253. doi: 10.1093/carcin/bgv038Thompson P. A., Khatami M., Baglole C. J., Sun J., Harris S. A., Moon E. Y. et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis. 2015;36(Suppl 1): S 232–253. doi: 10.1093/carcin/bgv038Рожкова Н. И., Подзолкова Н. М., Овсянникова Т. В. О роли пролактина в генезе заболеваний молочных желез. Status Praesens. 2016;4(33):1–9.Rozhkova N. I., Podzolkova N. M., Ovsyannikova T. V. On the role of prolactin in the genesis of breast diseases. Status Praesens. 2016;4(33):1–9.Salzano S., Checconi, Hanschmann E. M., Lillig C. H., Bowler L. D., Chan P. et al. Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proc. Natl. Acad. Sci. U S A. 2014;111(33):12157–12162. doi: 10.1073/pnas.1401712111Salzano S., Checconi, Hanschmann E. M., Lillig C. H., Bowler L. D., Chan P. et al. Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proc. Natl. Acad. Sci. U S A. 2014;111(33):12157–12162. doi: 10.1073/pnas.1401712111Покуль Л. В., Чугунова Н. А. Оксидативный стресс в генезе доброкачественных изменений молочных желез и возможности его коррекции. Doctor.Ru 2016;3(120):18–24.Pokul L. V., Chugunova N. A. Oxidative stress in the genesis of benign changes in the mammary glands and the possibility of its correction. Doctor.Ru 2016;3(120):18–24.Рожкова Н. И., Бурдина И. И., Запирова С. Б., Мазо М. Л., Прокопенко С. П., Якобс О. Э. Своевременное лечение диффузных гиперплазий – профилактика рака молочной железы. Онкогинекология. 2016; 1: 4–11.Rozhkova N. I., Burdina I. I., Zapirova S. B., Mazo M. L., Prokopenko S. P., Jacobs O. E. Timely treatment of diffuse hyperplasia – prevention of breast cancer. Oncogynecology. 2016; 1:4–11.Беспалов В. Г., Травина М. Л. Фиброзно-кистозная болезнь и риск рака молочной железы. Опухоли женской репродуктивной системы. 2015;11(4):58–70.Bespalov V. G., Travina M. L. Fibrocystic disease and the risk of breast cancer. Tumors of the female reproductive system. 2015;11(4):58–70.Гинекологическая эндокринология / под ред. Серова В. Н., Прилепской В. Н., Овсянниковой Т. В. М.: МЕДпресс-информ. 2017; 337–382.Gynecological endocrinology / ed. Serova V. N., Prilepskaya V. N., Ovsyannikova T. V. Moscow: MEDpress-inform. 2017; 337–382.Сутурина Л. В., Попова Л. Н. Динамика клинических симптомов и коррекция антиоксидантной недостаточности у женщин с диффузной мастопатией при использовании растительного препарата мастодинон. Акушерство и гинекология. 2012;8:56–59.Suturina L. V., Popova L. N. Dynamics of clinical symptoms and correction of antioxidant deficiency in women with diffuse mastopathy using the herbal preparation mastodinon. Obstetrics and Gynecology. 2012;8:56–59.Romagnolo D. F., Daniels K. D., Grunwald J. T., Ramos S. A., Propper C. R., Selmin O. I. Epigenetics of breast cancer: Modifying role of environmental and bioactive food compounds. Mol. Nutr. Food. Res. 2016;60(6):1310–1329. doi: 10.1002/mnfr.201501063Romagnolo D. F., Daniels K. D., Grunwald J. T., Ramos S. A., Propper C. R., Selmin O. I. Epigenetics of breast cancer: Modifying role of environmental and bioactive food compounds. Mol. Nutr. Food. Res. 2016;60(6):1310–1329. doi: 10.1002/mnfr.201501063Высоцкая И. В., Летягин В. П., Ким Е. А., Левкина Н. В. Практические рекомендации по лекарственной коррекции диффузной дисгормональной дисплазии молочных желез. Опухоли женской репродуктивной системы. 2014;2:45–52.Vysotskaya I. V., Letyagin V. P., Kim E. A., Levkina N. V. Practical recommendations for drug correction of diffuse dishormonal dysplasia of the mammary glands. Tumors of the female reproductive system. 2014;2:45–52.Высоцкая И. В., Летягин В. П., Ким Е. А., Погодина Е. М., Кирсанов В. Ю., Левкина Н. В. Рак молочной железы: от патогенеза к профилактике. Онкогинекология. 2018;4(28):31–38.Vysotskaya I. V., Letyagin V. P., Kim E. A., Pogodina E. M., Kirsanov V. Yu., Levkina N. V. Breast cancer: from pathogenesis to prevention. Oncogynecology. 2018;4(28):31–38.Хияева В. А. Опыт применения индолкарбинола при мастопатиях. Медицинский совет. 2019;13:154–158.Khiyaeva V. A. Experience in the use of indolecarbinol in mastopathy. Medical Council. 2019;13:154–158.Wang T. T.Y., Pham Q., Kim Y. S. Elucidating the Role of CD 84 and AHR in Modulation of LPS-Induced Cytokines Production by Cruciferous Vegetable-Derived Compounds Indole-3-Carbinol and 3,3’-Diindolylmethane. Int. J. Mol. Sci. 2018;19(2):339. doi: 10.3390/ijms19020339Wang T. T.Y., Pham Q., Kim Y. S. Elucidating the Role of CD 84 and AHR in Modulation of LPS-Induced Cytokines Production by Cruciferous Vegetable-Derived Compounds Indole-3-Carbinol and 3,3’-Diindolylmethane. Int. J. Mol. Sci. 2018;19(2):339. doi: 10.3390/ijms19020339Williams D. E. Indoles Derived from Glucobrassicin: Cancer Chemoprevention by Indole-3-Carbinol and 3,3’-Diindolylmethane. Front. Nutr. 2021;8:734334. doi: 10.3389/fnut.2021.734334Williams D. E. Indoles Derived from Glucobrassicin: Cancer Chemoprevention by Indole-3-Carbinol and 3,3’-Diindolylmethane. Front. Nutr. 2021;8:734334. doi: 10.3389/fnut.2021.734334Ашрафян Л. А., Бабаева Н. А., Антонова И. Б., Овчинникова О. А., Алешикова О. И., Моцкобили Т. А., Кузнецов И. Н. Уровень баланса эстрогеновых метаболитов при раке молочной железы и пути его коррекции. Опухоли женской репродуктивной системы. 2015;11(3):22–29. doi: 10.17650/1994–4098–2015–11–3–22–29.Ashrafyan L. A., Babaeva N. A., Antonova I. B., Ovchinnikova O. A., Aleshikova O. I., Motskobili T.A., Kuznetsov I. N. The level of balance of estrogen metabolites in breast cancer and ways of its correction. Tumors of the female reproductive system. 2015;11(3):22–29. doi: 10.17650/1994–4098–2015–11–3–22–29.Esteve M. Mechanisms Underlying Biological Effects of Cruciferous Glucosinolate-Derived Isothiocyanates/Indoles: A Focus on Metabolic Syndrome. Front. Nutr. 2020;7:111. doi: 10.3389/fnut.2020.00111Esteve M. Mechanisms Underlying Biological Effects of Cruciferous Glucosinolate-Derived Isothiocyanates/Indoles: A Focus on Metabolic Syndrome. Front. Nutr. 2020;7:111. doi: 10.3389/fnut.2020.00111Fuentes F., Paredes-Gonzalez X., Kong A. N. Dietary Glucosinolates Sulforaphane, Phenethyl Isothiocyanate, Indole-3-Carbinol/3,3’-Diindolylmethane: Anti-Oxidative Stress/Inflammation, Nrf2, Epigenetics/Epigenomics and in vivo Cancer Chemopreventive Efficacy. Curr. Pharmacol. Rep. 2015;1(3):179–196. doi: 10.1007/s40495–015–0017-yFuentes F., Paredes-Gonzalez X., Kong A. N. Dietary Glucosinolates Sulforaphane, Phenethyl Isothiocyanate, Indole-3-Carbinol/3,3’-Diindolylmethane: Anti-Oxidative Stress/Inflammation, Nrf2, Epigenetics/Epigenomics and in vivo Cancer Chemopreventive Efficacy. Curr. Pharmacol. Rep. 2015;1(3):179–196. doi: 10.1007/s40495–015–0017-yCaruso J. A., Campana R., Wei C., Su C. H., Hanks A. M., Bornmann W. G., Keyomarsi K. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells. Cell. Cycle. 2014;13(16):2587–2599. doi: 10.4161/15384101.2015.942210Caruso J. A., Campana R., Wei C., Su C. H., Hanks A. M., Bornmann W. G., Keyomarsi K. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells. Cell. Cycle. 2014;13(16):2587–2599. doi: 10.4161/15384101.2015.942210Maruthanila V. L., Poornima J., Mirunalini S. Attenuation of Carcinogenesis and the Mechanism Underlying by the Influence of Indole-3-carbinol and Its Metabolite 3,3’-Diindolylmethane: A Therapeutic Marvel. Adv. Pharmacol. Sci. 2014;2014 832161. doi: 10.1155/2014/832161Maruthanila V. L., Poornima J., Mirunalini S. Attenuation of Carcinogenesis and the Mechanism Underlying by the Influence of Indole-3-carbinol and Its Metabolite 3,3’-Diindolylmethane: A Therapeutic Marvel. Adv. Pharmacol. Sci. 2014;2014 832161. doi: 10.1155/2014/832161Сметник А. А., Сметник В. П., Киселев В. И. Опыт применения индол-3-карбинола в лечении заболеваний молочной железы и профилактике рака молочной железы // Акушерство и гинекология. 2017;2:106–112.Smetnik A. A., Smetnik V. P., Kiselev V. I. Experience in the use of indole-3-carbinol in the treatment of breast diseases and the prevention of breast cancer. Obstetrics and Gynecology. 2017;2:106–112.Semov A., Iourtchenco L., Liu L. F., Li S., Xu Y., Su X. et al. Diindolilmethane (DIM) selectively inhibits cancer stem cells. Biochem. Biophys. Res. Commun. 2012;424(1) 45–51. doi: 10.1016/j.bbrc.2012.06.062Semov A., Iourtchenco L., Liu L. F., Li S., Xu Y., Su X. et al. Diindolilmethane (DIM) selectively inhibits cancer stem cells. Biochem. Biophys. Res. Commun. 2012;424(1) 45–51. doi: 10.1016/j.bbrc.2012.06.062Meng T., Xiao D., Muhammed A., Deng J., Chen L., He J. Anti-Inflammatory Action and Mechanisms of Resveratrol. Molecules. 2021;26(1):229. doi: 10.3390/molecules26010229Meng T., Xiao D., Muhammed A., Deng J., Chen L., He J. Anti-Inflammatory Action and Mechanisms of Resveratrol. Molecules. 2021;26(1):229. doi: 10.3390/molecules26010229Hasan M., Bae H. An Overview of Stress-Induced Resveratrol Synthesis in Grapes: Perspectives for Resveratrol-Enriched Grape Products. Molecules. 2017;22(2):294. doi: 10.3390/molecules22020294Hasan M., Bae H. An Overview of Stress-Induced Resveratrol Synthesis in Grapes: Perspectives for Resveratrol-Enriched Grape Products. Molecules. 2017;22(2):294. doi: 10.3390/molecules22020294Meng Q., Guo T., Li G., Sun S., He S., Cheng B. et al. Dietary resveratrol improves antioxidant status of sows and piglets and regulates antioxidant gene expression in placenta by Keap1-Nrf2 pathway and Sirt1. J. Anim. Sci. Biotechnol. 2018;9:34. doi: 10.1186/s40104–018–0248-yMeng Q., Guo T., Li G., Sun S., He S., Cheng B. et al. Dietary resveratrol improves antioxidant status of sows and piglets and regulates antioxidant gene expression in placenta by Keap1-Nrf2 pathway and Sirt1. J. Anim. Sci. Biotechnol. 2018;9:34. doi: 10.1186/s40104–018–0248-yNunes S., Danesi F., Del Rio D., Silva P. Resveratrol and inflammatory bowel disease: the evidence so far. Nutr. Res. Rev. 2018;31(1):85–97. doi: 10.1017/S095442241700021XNunes S., Danesi F., Del Rio D., Silva P. Resveratrol and inflammatory bowel disease: the evidence so far. Nutr. Res. Rev. 2018;31(1):85–97. doi: 10.1017/S095442241700021XRamírez-Garza S.L., Laveriano-Santos E.P., Marhuenda-Muñoz M., Storniolo C. E., Tresserra-Rimbau A., Vallverdú-Queralt A., Lamuela-Raventós R. M. Health Effects of Resveratrol: Results from Human Intervention Trials. Nutrients. 2018;10(12):1892. doi: 10.3390/nu10121892Ramírez-Garza S.L., Laveriano-Santos E.P., Marhuenda-Muñoz M., Storniolo C. E., Tresserra-Rimbau A., Vallverdú-Queralt A., Lamuela-Raventós R. M. Health Effects of Resveratrol: Results from Human Intervention Trials. Nutrients. 2018;10(12):1892. doi: 10.3390/nu10121892Kukreja A., Wadhwa N., Tiwari A. Therapeutic role of resveratrol and piceatannol in disease prevention. Blood Disord. Transfus. 2014;5:9. doi: 10.4172/2155–9864.1000240Kukreja A., Wadhwa N., Tiwari A. Therapeutic role of resveratrol and piceatannol in disease prevention. Blood Disord. Transfus. 2014;5:9. doi: 10.4172/2155–9864.1000240Maleki Dana P., Sadoughi F., Mansournia M. A., Mirzaei H., Asemi Z., Yousefi B. Targeting Wnt signaling pathway by polyphenols: implication for aging and age-related diseases. Biogerontology. 202122(5):479–494. doi: 10.1007/s10522–021–09934-xMaleki Dana P., Sadoughi F., Mansournia M. A., Mirzaei H., Asemi Z., Yousefi B. Targeting Wnt signaling pathway by polyphenols: implication for aging and age-related diseases. Biogerontology. 202122(5):479–494. doi: 10.1007/s10522–021–09934-xNovakovic R, Rajkovic J, Gostimirovic M, Gojkovic-Bukarica L, Radunovic N. Resveratrol and Reproductive Health. Life (Basel). 2022; 12(2): 294. doi: 10.3390/life12020294Novakovic R, Rajkovic J, Gostimirovic M, Gojkovic-Bukarica L, Radunovic N. Resveratrol and Reproductive Health. Life (Basel). 2022; 12(2): 294. doi: 10.3390/life12020294Zhu W., Qin W., Zhang K., Rottinghaus G. E., Chen Y. C., Kliethermes B., Sauter E. R. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer. 201264(3):393–400. doi: 10.1080/01635581.2012.654926Zhu W., Qin W., Zhang K., Rottinghaus G. E., Chen Y. C., Kliethermes B., Sauter E. R. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer. 201264(3):393–400. doi: 10.1080/01635581.2012.654926Davinelli S., Scapagnini G., Marzatico F., Nobile V., Ferrara N., Corbi G. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study. Maturitas. 2017;96:77–83. doi: 10.1016/j.maturitas.2016.11.016Davinelli S., Scapagnini G., Marzatico F., Nobile V., Ferrara N., Corbi G. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study. Maturitas. 2017;96:77–83. doi: 10.1016/j.maturitas.2016.11.016Wong R. H., Evans H. M., Howe P. R.C. Resveratrol supplementation reduces pain experience by postmenopausal women. Menopause. 2017;24(8):916–922. doi: 10.1097/GME.0000000000000861Wong R. H., Evans H. M., Howe P. R.C. Resveratrol supplementation reduces pain experience by postmenopausal women. Menopause. 2017;24(8):916–922. doi: 10.1097/GME.0000000000000861Takeda M., Takehana S., Sekiguchi K., Kubota Y., Shimazu Y. Modulatory Mechanism of Nociceptive Neuronal Activity by Dietary Constituent Resveratrol. Int. J. Mol. Sci. 2016;17(10):1702. doi: 10.3390/ijms17101702Takeda M., Takehana S., Sekiguchi K., Kubota Y., Shimazu Y. Modulatory Mechanism of Nociceptive Neuronal Activity by Dietary Constituent Resveratrol. Int. J. Mol. Sci. 2016;17(10):1702. doi: 10.3390/ijms17101702Pan W., Yu H., Huang S., Zhu P. Resveratrol Protects against TNF-α-Induced Injury in Human Umbilical Endothelial Cells through Promoting Sirtuin-1-Induced Repression of NF-KB and p38 MAPK. PLoS One. 2016;11(1): e0147034. doi: 10.1371/journal.pone.0147034Pan W., Yu H., Huang S., Zhu P. Resveratrol Protects against TNF-α-Induced Injury in Human Umbilical Endothelial Cells through Promoting Sirtuin-1-Induced Repression of NF-KB and p38 MAPK. PLoS One. 2016;11(1): e0147034. doi: 10.1371/journal.pone.0147034de Sá Coutinho D., Pacheco M. T., Frozza R. L., Bernardi A. Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights. Int. J. Mol. Sci. 2018;19(6):1812. doi: 10.3390/ijms19061812de Sá Coutinho D., Pacheco M. T., Frozza R. L., Bernardi A. Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights. Int. J. Mol. Sci. 2018;19(6):1812. doi: 10.3390/ijms19061812Fuggetta M. P., Bordignon V., Cottarelli A., Macchi B., Frezza C., Cordiali-Fei P. et al. Downregulation of proinflammatory cytokines in HTLV-1-infected T cells by Resveratrol. J. Exp. Clin. Cancer. Res. 2016;35(1):118. doi: 10.1186/s13046–016–0398–8Fuggetta M. P., Bordignon V., Cottarelli A., Macchi B., Frezza C., Cordiali-Fei P. et al. Downregulation of proinflammatory cytokines in HTLV‑1-infected T cells by Resveratrol. J. Exp. Clin. Cancer. Res. 2016;35(1):118. doi: 10.1186/s13046–016–0398–8Ren Z., Wang L., Cui J., Huoc Z., Xue J., Cui H. et al. Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities. Pharmazie. 2013;68(8):689–694. PMID: 24020126Ren Z., Wang L., Cui J., Huoc Z., Xue J., Cui H. et al. Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities. Pharmazie. 2013;68(8):689–694. PMID: 24020126Magrone T., Magrone M., Russo M. A., Jirillo E. Recent Advances on the Anti-Inflammatory and Antioxidant Properties of Red Grape Polyphenols: In Vitro and In Vivo Studies. Antioxidants (Basel). 2019;9(1):35. doi: 10.3390/antiox9010035Magrone T., Magrone M., Russo M. A., Jirillo E. Recent Advances on the Anti-Inflammatory and Antioxidant Properties of Red Grape Polyphenols: In Vitro and In Vivo Studies. Antioxidants (Basel). 2019;9(1):35. doi: 10.3390/antiox9010035Turner R. S., Thomas R. G., Craft S., van Dyck C. H., Mintzer J., Reynolds B. A. et al. Alzheimer’s Disease Cooperative Study. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015; 85(16): 1383–1391. doi: 10.1212/WNL.0000000000002035.Turner R. S., Thomas R. G., Craft S., van Dyck C. H., Mintzer J., Reynolds B. A. et al. Alzheimer’s Disease Cooperative Study. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015; 85(16): 1383–1391. doi: 10.1212/WNL.0000000000002035.Moussa C., Hebron M., Huang X., Ahn J., Rissman R. A., Aisen P. S., Turner R. S. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J. Neuroinflammation. 2017;14(1):1. doi: 10.1186/s12974–016–0779–0Moussa C., Hebron M., Huang X., Ahn J., Rissman R. A., Aisen P. S., Turner R. S. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J. Neuroinflammation. 2017;14(1):1. doi: 10.1186/s12974–016–0779–0He S., Chen L., He Y., Chen F., Ma Y., Xiao D., He J. Resveratrol alleviates heat stress-induced impairment of intestinal morphology, barrier integrity and inflammation in yellow-feather broilers. Anim. Prod. Sci. 2020;60:1547. doi: 10.1071/AN 19218He S., Chen L., He Y., Chen F., Ma Y., Xiao D., He J. Resveratrol alleviates heat stress-induced impairment of intestinal morphology, barrier integrity and inflammation in yellow-feather broilers. Anim. Prod. Sci. 2020;60:1547. doi: 10.1071/AN 19218Bräunlich M., Slimestad R., Wangensteen H., Brede C., Malterud K. E., Barsett H. Extracts, anthocyanins and procyanidins from Aronia melanocarpa as radical scavengers and enzyme inhibitors. Nutrients. 2013;5(3):663–678. doi: 10.3390/nu5030663Bräunlich M., Slimestad R., Wangensteen H., Brede C., Malterud K. E., Barsett H. Extracts, anthocyanins and procyanidins from Aronia melanocarpa as radical scavengers and enzyme inhibitors. Nutrients. 2013;5(3):663–678. doi: 10.3390/nu5030663Xia N., Daiber A., Förstermann U., Li H. Antioxidant effects of resveratrol in the cardiovascular system. Br. J. Pharmacol. 2017174(12):1633–1646. doi: 10.1111/bph.13492Xia N., Daiber A., Förstermann U., Li H. Antioxidant effects of resveratrol in the cardiovascular system. Br. J. Pharmacol. 2017174(12):1633–1646. doi: 10.1111/bph.13492Yiu E. M., Tai G., Peverill R. E., Lee K. J., Croft K. D., Mori T. A. et al. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. J. Neurol. 2015;262(5):1344–53. doi: 10.1007/s00415–015–7719–2Yiu E. M., Tai G., Peverill R. E., Lee K. J., Croft K. D., Mori T. A. et al. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. J. Neurol. 2015;262(5):1344–53. doi: 10.1007/s00415–015–7719–2Chhabra G., Singh C. K., Amiri D., Akula N., Ahmad N. Recent Advancements on Immunomodulatory Mechanisms of Resveratrol in Tumor Microenvironment. Molecules. 2021;26(5):1343. doi: 10.3390/molecules26051343Chhabra G., Singh C. K., Amiri D., Akula N., Ahmad N. Recent Advancements on Immunomodulatory Mechanisms of Resveratrol in Tumor Microenvironment. Molecules. 2021;26(5):1343. doi: 10.3390/molecules26051343Talib W. H., Alsayed A. R., Farhan F., Al Kury L. T. Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets. Molecules. 2020;25(18):4282. doi: 10.3390/molecules25184282Talib W. H., Alsayed A. R., Farhan F., Al Kury L. T. Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets. Molecules. 2020;25(18):4282. doi: 10.3390/molecules25184282Hogg S. J., Chitcholtan K., Hassan W., Sykes P. H., Garrill A. Resveratrol, Acetyl-Resveratrol, and Polydatin Exhibit Antigrowth Activity against 3D Cell Aggregates of the SKOV-3 and OVCAR-8 Ovarian Cancer Cell Lines. Obstet. Gynecol. Int. 2015;2015:279591. doi: 10.1155/2015/279591Hogg S. J., Chitcholtan K., Hassan W., Sykes P. H., Garrill A. Resveratrol, Acetyl-Resveratrol, and Polydatin Exhibit Antigrowth Activity against 3D Cell Aggregates of the SKOV-3 and OVCAR-8 Ovarian Cancer Cell Lines. Obstet. Gynecol. Int. 2015;2015:279591. doi: 10.1155/2015/279591Liu Y., Tong L., Luo Y., Li X., Chen G., Wang Y. Resveratrol inhibits the proliferation and induces the apoptosis in ovarian cancer cells via inhibiting glycolysis and targeting AMPK/mTOR signaling pathway. J. Cell. Biochem. 2018;119(7):6162–6172. doi: 10.1002/jcb.26822Liu Y., Tong L., Luo Y., Li X., Chen G., Wang Y. Resveratrol inhibits the proliferation and induces the apoptosis in ovarian cancer cells via inhibiting glycolysis and targeting AMPK/mTOR signaling pathway. J. Cell. Biochem. 2018;119(7):6162–6172. doi: 10.1002/jcb.26822Li W., Ma J., Ma Q., Li B., Han L., Liu J. et al. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway. Curr. Med. Chem. 2013;20(33):4185–4194. doi: 10.2174/09298673113209990251Li W., Ma J., Ma Q., Li B., Han L., Liu J. et al. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway. Curr. Med. Chem. 2013;20(33):4185–4194. doi: 10.2174/09298673113209990251Nguyen M., Osipo C. Targeting Breast Cancer Stem Cells Using Naturally Occurring Phytoestrogens. Int J. Mol. Sci. 2022;23(12):6813. doi: 10.3390/ijms23126813.Nguyen M., Osipo C. Targeting Breast Cancer Stem Cells Using Naturally Occurring Phytoestrogens. Int J. Mol. Sci. 2022;23(12):6813. doi: 10.3390/ijms23126813.Wu H., Chen L., Zhu F., Han X., Sun L., Chen K. The Cytotoxicity Effect of Resveratrol: Cell Cycle Arrest and Induced Apoptosis of Breast Cancer 4T1 Cells. Toxins. (Basel). 2019;11(12):731. doi: 10.3390/toxins11120731Wu H., Chen L., Zhu F., Han X., Sun L., Chen K. The Cytotoxicity Effect of Resveratrol: Cell Cycle Arrest and Induced Apoptosis of Breast Cancer 4T1 Cells. Toxins. (Basel). 2019;11(12):731. doi: 10.3390/toxins11120731Castillo-Pichardo L., Cubano L. A., Dharmawardhane S. Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromised mice. BMC Complement. Altern. Med. 2013;13:6. doi: 10.1186/1472–6882–13–6Castillo-Pichardo L., Cubano L. A., Dharmawardhane S. Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromised mice. BMC Complement. Altern. Med. 2013;13:6. doi: 10.1186/1472–6882–13–6Zhu W., Qin W., Zhang K., Rottinghaus G. E., Chen Y. C., Kliethermes B.., Sauter ER. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer. 2012;64(3):393–400. doi: 10.1080/01635581.2012.654926Zhu W., Qin W., Zhang K., Rottinghaus G. E., Chen Y. C., Kliethermes B.., Sauter ER. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer. 2012;64(3):393–400. doi: 10.1080/01635581.2012.654926Alamolhodaei N. S., Tsatsakis A. M., Ramezani M., Hayes A. W., Karimi G. Resveratrol as MDR reversion molecule in breast cancer: An overview. Food. Chem. Toxicol. 2017;103:223–232. doi: 10.1016/j.fct.2017.03.024Alamolhodaei N. S., Tsatsakis A. M., Ramezani M., Hayes A. W., Karimi G. Resveratrol as MDR reversion molecule in breast cancer: An overview. Food. Chem. Toxicol. 2017;103:223–232. doi: 10.1016/j.fct.2017.03.024

The authors declare that there are no conflicts of interest present.